OPKO Health
Miami, Florida, United States · Biopharma, Biotechnology, Health Care
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and its novel and proprietary technologies. For more information, visit www.opko.com.
Key facts
- Headquarters
- Miami, Florida, United States
- Employees
- 3,000
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (OPK)
- Website
- www.opko.com
- Company page
Recent activity at OPKO Health
- : OPKO Health, Inc. secures $125 million in additional notes issuance from HealthCare Royalty, expanding its financing relationship. This capital is aimed at strengthening its balance sheet and retaining value from its mazdutide royalties.
- : OPKO Health Expands Partnership with Nicoya Therapeutics to Commercialize RAYALDEE in Greater China. (date Fundz recorded it)
- : SEC 8-K (1.01): On October 14, 2026, OPKO Health, Inc. and its subsidiary BioReference Health, LLC entered into a Material Definitive Agreement with Laboratory Corporation of America Holdings. The Asset Purchase Agreement involves the sale of assets from BioReference’s clinical and anatomic pathology laboratory testing business for an aggregate purchase price of $722,000,000 in cash, with potential additional payments of up to $150,000,000 over ten years linked to the revenue from the 4Kscore prostate cancer test. The agreement outlines customary closing conditions including HSR Clearance, and provides termination rights and a $28,880,000 fee under specific conditions related to regulatory approvals. This significant transaction enhances Buyer’s offerings in clinical health services and has strategic implications for both parties involved.
- : SEC 8-K (8.01): On October 1, 2026, OPKO Health, Inc. announced that its 3.75% Convertible Senior Notes due 2029, amounting to approximately $121 million outstanding, are now convertible by the holders until December 31, 2026. This conversion right was triggered as the company's common stock price exceeded $1.495 for at least 20 of the last 30 trading days, significantly above the conversion price of $1.15. The company has chosen to fulfill its conversion obligation with shares of common stock, indicating a potential dilution of existing shareholders but also reflecting the company's stock performance and investor confidence. Notably, the conversion conditions outlined in the Indenture allow for further conversions under certain future conditions, signaling ongoing financial flexibility for the company.
- : SEC 8-K (1.01): On August 13, 2026, OPKO Health, Inc. entered into an amendment to the initial Note Purchase Agreement dated July 17, 2024, with specific purchasers and its subsidiaries OPKO Biologics Ltd. and EirGen Pharma Limited acting as guarantors. The amendment involved the issuance of additional senior secured notes totaling $125,000,000, which will mature on July 17, 2044, bearing interest pegged to the 3-month Secured Overnight Financing Rate plus an additional 7.5%. These notes are secured by EirGen’s royalty interest under a license agreement with Eli Lilly for mazdutide sales and include provisions on the payment of interest and principal based on the royalty payments received. The agreement also imposes various customary covenants and terms for financial oversight and compliance. This amendment strengthens OPKO's financial structure and secures additional funding for its operations.
- : SEC 8-K (5.07): On June 18, 2026, OPKO Health, Inc. held its 2026 Annual Meeting of Stockholders where all eleven nominees were elected to the Board of Directors. The election results included significant votes for each nominee, indicating a strong support from the shareholders. Notably, Phillip Frost, M.D. received 423,666,978 votes in favor while Jane H. Hsiao, Ph.D. garnered 422,928,151 votes, highlighting their prominent positions on the board. The approval of these directors is expected to influence the company's strategic direction and governance practices moving forward.
- : SEC 8-K (5.02): On March 18, 2026, OPKO Health, Inc. appointed Subbarao V. Uppaluri, Ph.D. as a new director, following the vacancy left by the passing of Dr. Richard Krasno. Dr. Uppaluri's appointment is effective immediately and will last until the 2026 Annual Meeting of Stockholders. He will also likely join the Compensation Committee of the Board, emphasizing the Company's commitment to board independence as he is deemed independent under SEC and Nasdaq rules. Dr. Uppaluri has extensive experience in senior financial roles, including his time as Senior VP and CFO at the Company, enhancing the Board's expertise in financial oversight.
- : OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments (date Fundz recorded it)
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
OPKO Health funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Debt Financing | $125.0M |
Leadership
- Luis Paredes, Director, Project Management (PMO), Includes Operations and Supply Chain
- Gregory, SVP, HR
- Asfand Khaliq, Chief Product Officer
Verified email and direct lines for OPKO Health’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
OPKO Health files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
OPKO Health in the news
- November 8, 2022 - EX-99.1 - 8-K: Current report filing - OPKO Health, Inc. (Nov 08, 2022)
- OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months - Yahoo Finance (Sep 11, 2026)
- Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health - PR Newswire (Oct 15, 2026)
- OPKO Health Expands Strategic Relationship with HealthCare - GlobeNewswire (Aug 13, 2026)
- OPKO Health (Nasdaq:OPK) - Stock Analysis - Simply Wall St (May 17, 2022)
- OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly - Yahoo Finance (Oct 27, 2026)
- OPKO Health (OPK) Stock Price, News & Analysis $OPK - MarketBeat (Aug 12, 2016)
- OPKO Health, Inc. (OPK) Company Profile & Facts - Yahoo! Finance Canada (May 19, 2017)
Companies similar to OPKO Health
- Jazz Pharmaceuticals plc · Biopharma, Biotechnology, Health Care
- Alnylam Pharmaceuticals · Biopharma, Biotechnology, Health Care
- GC Biopharma · Biopharma, Biotechnology, Health Care
- Foresee Pharmaceuticals · Biopharma, Biotechnology, Health Care
- Daiichi Sankyo · Biopharma, Biotechnology, Health Care
About OPKO Health: questions and answers
What does OPKO Health do?
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and its novel and proprietary technologies. For more information, visit www.opko.com.
Where is OPKO Health headquartered?
OPKO Health is headquartered in Miami, Florida, United States.
How many employees does OPKO Health have?
OPKO Health has about 3,000 employees.
Has OPKO Health raised funding?
Yes. Fundz has recorded 1 funding event for OPKO Health. The most recent, Debt Financing of $125.0M, was in Aug 2026.
What is the latest news on OPKO Health?
On Aug 13, 2026, OPKO Health, Inc. secures $125 million in additional notes issuance from HealthCare Royalty, expanding its financing relationship. This capital is aimed at strengthening its balance sheet and retaining value from its mazdutide royalties.
Is OPKO Health a public company?
Yes. OPKO Health is publicly traded under the ticker OPK.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy